Saudi Arabia’s Local Content and Government Procurement Authority (LCGPA) has signed a preliminary agreement with National Unified Procurement (NUPCO), SUDAIR PHARMACEUTICAL COMPANY, and Sanofi in order to localize the manufacture and transfer of knowledge of insulin products.
The agreement was signed on the sidelines of the Global Health Forum under the patronage of the Chairman of the authority’s Board of Directors, Mr. Bandar bin Ibrahim Al-Khorayef, and the Ministers of Investment and Health, Eng. Khalid bin Abdulaziz Al-Falih and Minister of Health Mr. Fahd bin Abdulrahman Al-Jalajel, respectively.
The CEO of the authority, Mr. Abdulrahman bin Abdullah Al-Samari, said that the localization of the manufacture and transfer of knowledge of insulin products is a top priority for the health sector, adding that “it will contribute to the development of local content in the pharmaceutical industry, in line with the Health Sector Transformation Program, which is one of the Kingdom’s Vision 2030 programs.”
Mr. Al-Samari noted that the Local Content and Government Procurement Authority has contributed to promoting preventive health through several quality initiatives that are consistent with the efforts of the Vaccines and Biopharmaceuticals Industry Committee and the Treatments Localization and Development Committee working towards localizing priority industries to achieve health and drug security.
Furthermore, the CEO of the authority expressed his appreciation for all government agencies that participated in the agreement, including the Ministry of Health and the Government Expenditure and Projects Efficiency Authority.
Last year, LCGPA signed seven agreements to localize the pharmaceutical industry and transfer knowledge, including four agreements with Tabuk Pharmaceuticals and three with the Saudi Pharmaceutical Industries and Medical Appliances Corporation (SPIMACO).
